Publication Information

{'id': 'https://openalex.org/W1984313504', 'doi': 'https://doi.org/10.1586/erp.09.1', 'title': 'Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia', 'display_name': 'Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia', 'publication_year': 2009, 'publication_date': '2009-04-01', 'ids': {'openalex': 'https://openalex.org/W1984313504', 'doi': 'https://doi.org/10.1586/erp.09.1', 'mag': '1984313504', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/19402798'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1586/erp.09.1', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S98544388', 'display_name': 'Expert Review of Pharmacoeconomics & Outcomes Research', 'issn_l': '1473-7167', 'issn': ['1473-7167', '1744-8379'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'review', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5045462330', 'display_name': 'Matthew Taylor', 'orcid': 'https://orcid.org/0000-0003-4716-4662'}, 'institutions': [{'id': 'https://openalex.org/I52099693', 'display_name': 'University of York', 'ror': 'https://ror.org/04m01e293', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I52099693']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Matthew J Taylor', 'raw_affiliation_strings': ['Senior Consultant, York Health Economics Consortium Ltd, Market Square, University of York, York, YO10 5NH, UK. [email protected]'], 'affiliations': [{'raw_affiliation_string': 'Senior Consultant, York Health Economics Consortium Ltd, Market Square, University of York, York, YO10 5NH, UK. [email protected]', 'institution_ids': ['https://openalex.org/I52099693']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5057811148', 'display_name': 'Paul Scuffham', 'orcid': 'https://orcid.org/0000-0001-5931-642X'}, 'institutions': [{'id': 'https://openalex.org/I11701301', 'display_name': 'Griffith University', 'ror': 'https://ror.org/02sc3r913', 'country_code': 'AU', 'type': 'education', 'lineage': ['https://openalex.org/I11701301']}], 'countries': ['AU'], 'is_corresponding': False, 'raw_author_name': 'Paul A Scuffham', 'raw_affiliation_strings': ['Chair in Health Economics, Griffith University, Queensland, Australia'], 'affiliations': [{'raw_affiliation_string': 'Chair in Health Economics, Griffith University, Queensland, Australia', 'institution_ids': ['https://openalex.org/I11701301']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 2, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.34, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 9, 'citation_normalized_percentile': {'value': 0.231546, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 83, 'max': 84}, 'biblio': {'volume': '9', 'issue': '2', 'first_page': '117', 'last_page': '121'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11215', 'display_name': 'Chronic Myeloid Leukemia Treatments', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11215', 'display_name': 'Chronic Myeloid Leukemia Treatments', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12600', 'display_name': 'Eosinophilic Disorders and Syndromes', 'score': 0.9963, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Chronic Lymphocytic Leukemia Research', 'score': 0.9913, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/chronic-myelogenous-leukemia', 'display_name': 'Chronic myelogenous leukemia', 'score': 0.92971903}, {'id': 'https://openalex.org/keywords/imatinib-mesylate', 'display_name': 'Imatinib Mesylate', 'score': 0.49424604}, {'id': 'https://openalex.org/keywords/abl', 'display_name': 'ABL', 'score': 0.43705302}], 'concepts': [{'id': 'https://openalex.org/C2779536868', 'wikidata': 'https://www.wikidata.org/wiki/Q419940', 'display_name': 'Dasatinib', 'level': 4, 'score': 0.9619704}, {'id': 'https://openalex.org/C2776960273', 'wikidata': 'https://www.wikidata.org/wiki/Q729735', 'display_name': 'Chronic myelogenous leukemia', 'level': 3, 'score': 0.92971903}, {'id': 'https://openalex.org/C2777583451', 'wikidata': 'https://www.wikidata.org/wiki/Q177094', 'display_name': 'Imatinib', 'level': 3, 'score': 0.9033263}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8141458}, {'id': 'https://openalex.org/C2778461978', 'wikidata': 'https://www.wikidata.org/wiki/Q29496', 'display_name': 'Leukemia', 'level': 2, 'score': 0.5384884}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.51308787}, {'id': 'https://openalex.org/C3019892230', 'wikidata': 'https://www.wikidata.org/wiki/Q177094', 'display_name': 'Imatinib mesylate', 'level': 4, 'score': 0.49424604}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.48626196}, {'id': 'https://openalex.org/C125418893', 'wikidata': 'https://www.wikidata.org/wiki/Q587961', 'display_name': 'ABL', 'level': 4, 'score': 0.43705302}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.39714608}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.15074456}, {'id': 'https://openalex.org/C2778729363', 'wikidata': 'https://www.wikidata.org/wiki/Q11688946', 'display_name': 'Myeloid leukemia', 'level': 2, 'score': 0.10916817}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.06155029}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D000818', 'descriptor_name': 'Animals', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001549', 'descriptor_name': 'Benzamides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003365', 'descriptor_name': 'Costs and Cost Analysis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069439', 'descriptor_name': 'Dasatinib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019008', 'descriptor_name': 'Drug Resistance, Neoplasm', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068877', 'descriptor_name': 'Imatinib Mesylate', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D011788', 'descriptor_name': 'Quality of Life', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016896', 'descriptor_name': 'Treatment Outcome', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1586/erp.09.1', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S98544388', 'display_name': 'Expert Review of Pharmacoeconomics & Outcomes Research', 'issn_l': '1473-7167', 'issn': ['1473-7167', '1744-8379'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320547', 'host_organization_name': 'Taylor & Francis', 'host_organization_lineage': ['https://openalex.org/P4310320547'], 'host_organization_lineage_names': ['Taylor & Francis'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/19402798', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.43}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 9, 'referenced_works': ['https://openalex.org/W1970962784', 'https://openalex.org/W1975185750', 'https://openalex.org/W2009563819', 'https://openalex.org/W2011474502', 'https://openalex.org/W2079517811', 'https://openalex.org/W2107268345', 'https://openalex.org/W2116153687', 'https://openalex.org/W2126579741', 'https://openalex.org/W2315329255'], 'related_works': ['https://openalex.org/W4253096022', 'https://openalex.org/W2941817612', 'https://openalex.org/W2618548116', 'https://openalex.org/W2184534421', 'https://openalex.org/W2113703021', 'https://openalex.org/W2092828011', 'https://openalex.org/W2091813747', 'https://openalex.org/W2070391470', 'https://openalex.org/W1984313504', 'https://openalex.org/W1983852790'], 'abstract_inverted_index': {'Treatment': [0], 'with': [1, 37, 45, 57, 115, 122, 128, 139], 'imatinib': [2, 21, 38], 'has': [3, 53, 69], 'demonstrated': [4], 'high': [5], 'response': [6, 19, 31, 36, 126, 136], 'rates': [7], 'and': [8, 60, 101, 112, 148], 'improved': [9, 140], 'prognosis': [10], 'in': [11, 43, 107, 143], 'chronic': [12, 74, 116], 'myelogenous': [13, 75, 117], 'leukemia.': [14, 118], 'However,': [15], 'while': [16], 'the': [17, 29, 93, 97, 108], 'short-term': [18], 'to': [20, 41, 88], 'is': [22, 32, 39, 63, 120], 'high,': [23], 'there': [24], 'are': [25, 84, 137], 'some': [26], 'concerns': [27], 'that': [28, 68], 'long-term': [30], 'substantially': [33], 'lower.': [34], 'Durable': [35], 'difficult': [40], 'achieve': [42], 'patients': [44, 114], 'resistant': [46, 85], 'disease.': [47], 'The': [48], 'use': [49], 'of': [50, 81, 105, 110, 125, 135, 145], 'higher': [51, 123, 133], 'doses': [52], 'also': [54], 'been': [55, 70], 'associated': [56, 121, 138], 'increased': [58], 'toxicity': [59], 'intolerance.': [61], 'Dasatinib': [62, 119], 'a': [64], 'new': [65], 'SRC–ABL-kinase': [66], 'inhibitor': [67], 'developed': [71], 'for': [72, 103], 'treating': [73], 'leukemia': [76], 'patients,': [77], 'across': [78], 'all': [79], 'phases': [80], 'disease,': [82], 'who': [83], 'or': [86], 'intolerant': [87], 'imatinib.': [89, 130], 'This': [90], 'article': [91], 'details': [92], 'existing': [94], 'evidence': [95], 'on': [96], 'clinical': [98], 'efficacy,': [99], 'safety': [100], 'value': [102], 'money': [104], 'dasatinib': [106], 'treatment': [109], 'imatinib-resistant': [111], '-intolerant': [113], 'levels': [124, 134], 'compared': [127], 'high-dose': [129], 'In': [131], 'addition,': [132], 'health': [141], 'outcomes': [142], 'terms': [144], 'both': [146], 'quality-': [147], 'quantity-of-life': [149], 'years.': [150]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W1984313504', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2015, 'cited_by_count': 1}, {'year': 2013, 'cited_by_count': 1}], 'updated_date': '2024-12-10T14:45:21.423481', 'created_date': '2016-06-24'}